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Abstract 
Purpose: To report 2 cases of Vogt-Koyanagi-Harada disease accompanied by remarkable 
choroidal folds in the acute stage. The early indicator of recurrence in these 2 cases was the 
identification of choroidal folds by spectral-domain optical coherence tomography (SD-OCT).  
Case Reports: A 68-year-old woman (Case 1) presented with visual loss in both eyes. 
Funduscopic examination revealed optic disc swelling and serous retinal detachment in both 
eyes. SD-OCT revealed remarkable choroidal folds and serous retinal detachment. After the 
initiation of systemic steroid treatment, choroidal folds disappeared rapidly and the amount 
of serous retinal detachment reduced remarkably. Choroidal folds observed on SD-OCT were 
the early indicators of recurrence prior to the emergence of serous retinal detachment. A 
62-year-old woman (Case 2) presented with bilateral blurred vision and metamorphopsia. 
SD-OCT showed remarkable choroidal folds and serous retinal detachment in both eyes. 
After the initiation of systemic steroid treatment, choroidal folds and serous retinal 
detachment disappeared. At the time of recurrence, choroidal folds were observed by OCT.  
Discussion: During monitoring of Vogt-Koyanagi-Harada disease treatment, choroidal folds 
could be an early sign of recurrence. When choroidal folds are observed and recognized as 
an early indicator of recurrence, a prompt increase in steroids can improve the patients’ 
prognosis. Finally, both cases presented here had relatively short axial lengths, and we 
speculate that a shortened axial length may be a cause of choroidal folds in the acute stage 
of the disease. 
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Case Reports 
Case 1 
A 68-year-old woman presented with visual loss in both eyes, which had persisted for 1 month. 
Best-corrected visual acuity (BCVA) measured using the Landolt ring chart was 0.4 in her right eye 
and 0.3 in her left eye. No remarkable findings or inflammation was observed in the anterior segment 
of either eye. Funduscopic examination revealed optic disc swelling and serous retinal detachment in 
both eyes (fig. 1a, b). Fluorescein angiography (FA) revealed remarkable leakage of the dye from the 
optic disc and retina in both eyes in the early phase, and subretinal dye pooling in both eyes was 
observed in the late phase (fig. 1c, d). Spectral-domain optical coherence tomography (SD-OCT; 
Cirrus® HD OCT; Carl Zeiss Meditec, Tokyo, Japan) revealed remarkable choroidal folds and serous 
retinal detachment in both eyes (fig. 1e, f). The patient also complained of headache and tinnitus. 
Brain MRI showed no intracranial mass lesion. Vogt-Koyanagi-Harada (VKH) disease was diagnosed 
on the basis of the patient’s medical history as well as of her FA and SD-OCT findings. Steroid pulse 
therapy consisting of 1,000 mg methylprednisolone was intravenously administered for 3 days, 
followed by oral steroid tapering (fig. 2). After the initiation of systemic steroid treatment, SD-OCT 
showed that choroidal folds disappeared rapidly and the amount of serous retinal detachment 
reduced remarkably. BCVA improved to 1.0 in the right eye and 0.9 in the left eye before disease 
recurrence, which was confirmed by an OCT image showing serous retinal detachment (fig. 3c). OCT 
detected choroidal folds 2 months before the emergence of serous retinal detachment (fig. 3b). At the 
time of recurrence, BCVA had not deteriorated and the patient did not complain of any visual 
disturbances. Steroid pulse therapy consisting of 1,000 mg methylprednisolone was initiated again for 
3 days, followed by oral steroid tapering. After the re-introduction of steroid pulse therapy, SD-OCT 
showed disappearance of the choroidal folds. The patient is now stabilized without medication and 
observed periodically. Finally, axial lengths of her eyes were relatively short, 21.84 mm in the right 
eye and 21.87 mm in the left eye, as determined by A-mode echo measurement during disease 
remission. 
Case 2 
A 62-year-old woman presented with bilateral blurred vision that had persisted for 1 week and 
metamorphopsia that had emerged the day before. On her first visit, the patient’s BCVA was 0.8 in her 
right eye and 0.5 in her left eye. She also suffered from headaches and tinnitus for 1 week. 
Funduscopic examination revealed serous retinal detachment in both eyes without optic disc swelling 
(fig. 4a, b). SD-OCT showed remarkable choroidal folds and mutilobular serous retinal detachment in 
both eyes with the presence of subretinal septa (fig. 4c, d). After VKH diagnosis, systemic steroid 
therapy consisting of 250 mg methylprednisolone was initiated and tapered (fig. 5). After systemic 
steroid therapy initiation, SD-OCT showed that choroidal folds disappeared and the amount of serous 
retinal detachment remarkably reduced in both eyes. BCVA improved to 0.9 in the right eye and 0.9 in 
the left eye before disease recurrence. At the time of recurrence, choroidal folds were detected by OCT 
and funduscopic examination, and the patient again started complaining of metamorphopsia (fig. 4e, 
f). The amount of methylprednisolone was increased to 40 mg per day and was tapered again. After 
the increase in steroids administered, the patient recovered from metamorphopsia, and SD-OCT 
showed disappearance of the choroidal folds. The patient is now stabilized with 5 mg 
methylprednisolone and observed periodically. Axial lengths of her eyes were relatively short, 22.49 
mm in the right eye and 22.63 mm in the left eye, as determined by A-mode echo measurement during 
disease remission. 
Discussion 
Serous retinal detachment and subretinal septa are commonly observed on OCT in 
the acute stage of VKH disease, and FA shows leakage of the dye from the retina in the 
early phase and subretinal dye pool in the late phase [1–3]. Choroidal folds identified 
by SD-OCT are a recently reported finding in the acute stage of VKH disease [4, 5]. In 
addition, Maruko et al. [6] reported that, in the acute stage, VKH disease cases 
presented with a thickening of the choroid. The underlying mechanism of choroidal fold 
formation remains unknown. Case Rep Ophthalmol 2012;3:38–45 
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In a previous report, choroidal folds were observed in 12% of VKH disease patients 
in the acute stage [4]. As shown in our 2 cases, choroidal fold identification by SD-OCT 
was useful as an early indicator of VKH disease recurrence during the course of 
treatment. SD-OCT images of Case 1 showed that localized serous retinal detachment 
emerged 2 months after the choroidal folds were detected again by SD-OCT after 
remission. 
To date, intractable cases of VKH disease have proven to be problematic for the 
attending physicians. We speculate that among the intractable cases of VKH disease, 
there are recurring cases that have remained untreated for a long time, which was 
sufficient to destroy the retinal pigment epithelium and sensory retinal function 
because of the difficulty in detecting disease recurrence. For example, patients might 
have only slight choroidal folds or serous retinal detachment without remarkable visual 
acuity deterioration. However, SD-OCT allows physicians to identify disease recurrence 
earlier and re-start steroid therapy sooner, probably resulting in better prognosis as 
shown in Case 2. 
It is also interesting to note that in both cases presented here, the patients had 
relatively short axial lengths and both experienced disease recurrence with choroidal 
folds as a preceding sign of acute inflammation. Wu et al. [4] hypothesized that marked 
congestion and thickness of choroids cause folding in order to adapt the unchanged 
intraocular volume. We speculate that limited ocular globe volume and fulminant 
inflammation could be factors causing choroidal folds in the acute stage. In limited 
spaces, such as in the relatively small ocular globe, acute inflammation causes 
thickening of the choroid adjacent to the solid sclera. There is a possibility that 
thickened choroidal structures are confined in the relatively small ocular globes and 
become voluminous and form choroidal folds in the acute stage of the disease. We also 
speculate that extraordinary thickening of the choroids caused by fulminant 
inflammation may cause choroidal folds in ordinary-sized ocular globes. 
It is unknown whether eyes with choroidal folds or shortened axial lengths are more 
likely to suffer from VKH disease recurrence. Our experience using SD-OCT in VKH 
disease cases is limited, and more cases are needed to verify our hypothesis that eyes 
with shortened axial lengths may tend to have choroidal folds and thus may be more 
likely to experience VKH disease recurrence. Recently, enhanced depth imaging OCT 
has been reported to allow evaluation of choroidal thickness [6]. Considering such 
technological advances, more detailed analyses of the ocular globe structure in the 
acute stage of VKH disease are expected in the future. 
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Fig. 1. a, b Fundus photography of optic disc swelling and serous retinal detachment in both eyes of 
Case 1 before treatment. c, d FA showing remarkable dye staining of the optic disc and subretinal dye 
pooling in both eyes in the late phase. e, f SD-OCT showing remarkable choroidal folds and serous 
retinal detachment in both eyes. 
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Fig. 2. Doses of methylprednisolone and treatment course of Case 1. Day 1 indicates the first day on 
which steroids were administered. On day 105, choroidal folds were detected by OCT. On day 154, 
serous retinal detachment was detected by OCT. Steroid pulse therapy was initiated again. 
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Fig. 3. OCT images of Case 1. a Choroidal folds rapidly disappeared and the amount of serous retinal 
detachment was reduced remarkably on day 13 after the initiation of steroid therapy. b Choroidal 
folds re-formed on day 105. c Serous retinal detachment appeared in the left eye and choroidal folds 
were enhanced on day 154. 
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Fig. 4. a, b Fundus photography showing serous retinal detachment in both eyes of Case 2 before 
treatment. c, d SD-OCT showing choroidal folds and serous retinal detachment with the presence of 
subretinal septa before treatment. e, f SD-OCT images showing choroidal fold formation on day 63 
after the initiation of steroid therapy. 
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Fig. 5. Doses of methylprednisolone and treatment course of Case 2. Day 1 indicates the first day on 
which steroids were administered. On day 63, choroidal folds were detected by OCT and funduscopic 
examination. On day 64, the steroid was increased to 40 mg/day. 
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